solid gardasil broad portfolio
beat revenue/ep gardasil strong ex-u
sale y/i our/con estim driven gardasil
broad-bas strength across portfolio mrk top sale growth driver keytruda
report global sale growth y/i rel in-lin forecast
thu make meaning chang product forecast non-gaap ep
grew y/i beat our/con estim growth aid
favor oper leverag base perform updat guidanc
tweak sale out-year
driven modest increas gardasil partial off-set slightli lower anim health
reiter buy rate slightli increas po base
gardasil keytruda upsid potenti margin expans undemand valuat
takeaway call
takeaway china trend management field numer question light continu
strong trend merck china-bas busi y/i management broadli
attribut pivot innov chines drug market keytruda show
strong sale keytruda metastat melanoma management express
excit opportun lung compani work china nrdl
process possibl list management note potenti get coupl
hundr thousand lung cancer patient china us keytruda lung
launch lung remain key growth driver us y/i sale
indic growth aid fast uptak patient squamou histolog
share share non-squam remain low management view
nsclc rcc approv april hnscc pdufa june
near-term us growth driver busi develop management remain
focus bolt-on deal note valuat target seem full
compar end valuat get attract us drug
price management gener deflect question regard impact administr
propos medicar part intern price index management declin
provid ex-u net price keytruda note earli day administr
propos question calcul use arriv us/row price differenti
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
hnscc- head neck squamou cell
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
price object po base blend averag risk-adjust
discount cash flow dcf price-to-earnings multipl appli ep dcf assum
wacc termin growth rate believ dcf assumpt
reason given minim contribut new keytruda indic
yet valid late-stag clinic studi erod revenu base
januvia/janumet zepati neg termin growth target price-to-earnings
multipl base regress analysi histor us major pharma
forward price-to-earnings multipl three-year forward compound-annual-growth-rate non-gaap
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip price pressur
diabet franchis neg result late-stag clinic program
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
